The Truth Gender Clinicians Tried to Ignore - Dr Susan Bradley (#43)
Dr Susan Bradley co-founded Canada's first paediatric gender clinic in 1975 and spent nearly fifty years treating gender-dysphoric children. She tells Beyond Gender that puberty blockers are not reversible and function as a pipeline to cross-sex hormones, that most gender-dysphoric children who were not medically intervened upon grew up gay or lesbian, and that clinicians who raised concerns were systematically silenced. Her evidence maps directly onto the conclusions of the Cass Review and the history of the Tavistock, making this episode essential listening for anyone trying to understand how Britain arrived where it did.
Dr Susan Bradley is not a commentator arriving late to a controversy. She co-founded Canada's first paediatric gender clinic in 1975, treated more than four hundred gender-dysphoric children over nearly five decades, and chaired the DSM-IV subcommittee on gender identity disorders. When she says the field took a catastrophically wrong turn, she speaks as someone who watched it happen from the inside — and who followed individual patients for forty years to see the consequences. The claim that will resonate most for British listeners is her verdict on puberty blockers. Bradley does not believe they are reversible. Presented to families across the NHS and elsewhere as a safe pause that gave children time to think, the blockers were in practice the entrance to a one-way corridor: once children started taking them, nearly ninety per cent went on to cross-sex hormones. This is the same trajectory that alarmed the Cass Review and ultimately led NHS England to restrict and then ban puberty blockers for gender-dysphoric under-eighteens. Bradley's clinical observation, drawn from decades of direct patient care, arrives at the same destination the Cass Review reached through systematic evidence review. She also records that the majority of gender-dysphoric children who came through her clinic without medical intervention grew up to be gay or lesbian. One patient, a boy who arrived aged nine convinced he was female, later identified as gay after finding community and connection with other young people. Bradley is clear: what that boy needed was not a clinical pathway but a sense of belonging. For Britain, this matters in a specific way. The proposed conversion therapy ban has been repeatedly delayed because legislators cannot agree whether watchful waiting or exploratory therapy for gender-dysphoric children would fall foul of the law. Bradley's case histories are a clinical argument that the question has been framed the wrong way round. The episode returns to the 2015 dismissal of Dr Ken Zucker from CAMH, Bradley's colleague, after an activist-led campaign accused the clinic of practising conversion therapy. CAMH later apologised and paid Zucker $586,000 in settlement. British listeners will hear an echo. Clinicians at the Tavistock who raised concerns about caseload composition, the pace of affirmation, or the absence of long-term outcome data faced similar professional consequences. The silencing of dissenting clinical voices was not unique to Canada; it was a transatlantic phenomenon that delayed the reckoning in both countries. Bradley also highlights the significantly elevated rate of autism among trans-identified young people, noting that autistic individuals, once they have identified a solution to their distress, can struggle to entertain alternatives. The Cass Review flagged exactly this safeguarding gap — that the GIDS model did not routinely provide the specialist autism assessment that so many of its referrals required. Her testimony is a reminder that the failures uncovered in Britain were part of something wider. The Cass Review gave this country a formal accounting. Dr Bradley offers the view from the clinic floor, over fifty years, from the professional generation that built the system and watched it be captured.
